<DOC>
	<DOCNO>NCT01498068</DOCNO>
	<brief_summary>The purpose study determine effectiveness , safety tolerability telaprevir administer 750 mg every 8 hour ( q8h ) combination pegylated interferon ( Peg-IFN ) -alfa-2a ribavirin ( RBV ) treatment-na誰ve treatment-experienced Russian participant genotype 1 chronic hepatitis C .</brief_summary>
	<brief_title>Open-Label , Bridging Study Telaprevir Treatment-Na誰ve Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description>This open-label ( person know study drug assignment ) , multicenter study treatment-na誰ve ( participant receive previous treatment treatment hepatitis C ) treatment-experienced ( participant receive previous treatment hepatitis C ) Russian participant genotype 1 chronic hepatitis C. After screen period approximately 4 week , participant treat 12 week telaprevir 750 mg every 8 hour combination Peg-IFN-alfa-2a RBV follow 12 36 week treatment Peg-IFN-alfa-2a RBV alone depend liver disease status , response previous treatment individual virologic response treatment study . After treatment period , follow-up phase least 12 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participant genotype 1 chronic hepatitis C HCV RNA level &gt; 1000 IU/mL Participant either treatmentna誰ve receive previous treatment approve investigational drug drug regimen treatment hepatitis C , participant treatmentexperienced achieve sustain virologic response ( SVR ) 24 week least 1 prior course PegIFN/RBV therapy ( nullresponder , partialresponder viral relapse ) Participant must documentation liver biopsy fibroscan within 2 year screen visit agree biopsy fibroscan within screen period unless histological cirrhosis demonstrate biopsy fibroscan &gt; 2 year ago prior screen A female participant childbearing potential nonvasectomized male participant female partner childbearing potential must agree use 2 effective method birth control screen 6 month ( female participant ) 7 month ( male participant ) last dose RBV Prior nonresponder classify viral breakthrough participant Participant infect coinfected HCV another genotype genotype 1 Participant history decompensated liver disease show evidence significant liver disease addition hepatitis C Participant human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) coinfection Participant active malignant disease history malignant disease within past 5 year ( exception treat basal cell carcinoma hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Genotype 1 chronic Hepatitis C</keyword>
	<keyword>VX-950HPC3007</keyword>
	<keyword>VX-950</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>HCV</keyword>
</DOC>